US 9,539,210 B2Granted

Vaccine nanotechnology

AssigneesMassachusetts Institute of Technology, The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation

InventorsUlrich H. von Andrian, Omid C. Farokhzad, Robert S. Langer, Tobias Junt, Elliott Ashley Moseman, Liangfang Zhang, Pamela Basto, Matteo Iannacone, Frank Alexis

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.

Claims17

Dependent claims

A composition to induce tolerance to an antigen comprising polymeric nanocarriers having a diameter of between 60 nm and 400 nm, formed from the self-assembly of polymers selected from the group consisting of polyhydroxyacids, polyanydrides, polyethylene glycols, polyoxyethyleneoxides, poly(ortho esters), poly(caprolactones), polylysines, poly(ethylene imines), copolymers and block copolymers thereof,

Wherein the nanoparticles selectively target the subcapsular macrophages and dendritic cells in the draining lymph nodes, and
wherein the nanocarriers comprise
(i) immunosuppressant selected from the group consisting of TGF-β, a rapamycin, retinoic acid, cyclosporin, steroids, and methotrexate encapsulated in the nanocarriers,
(ii) an antigen selected from the group consisting of allergic antigens and autoantigens, the antigen encapsulated within the nanocarrier, on the surface of the nanocarriers, or bound to a polymer from which the nanocarriers are formed;
and
Wherein the nanocarriers are in an effective amount to induce tolerance to the antigen when administered to a human or animal.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application: 13/844,382Filed 15 Mar 2013 · continuation
Priority: 12 Oct 2007
Published: US 2014/0314865 A123 Oct 2014
Granted: 10 Jan 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification50 codes

A61K 9/14
Medicinal preparations characterised by special physical form: particulate form, e.g. powders, Processes for size reducing of pure drugs or the…
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…

Family

Application60/979,596Us provisional application · filed 12 Oct 2007
PCT/US2008/011932Parent of this continuation · filed 12 Oct 2008
US 2014/0314865 A1Pre-grant publication · published 23 Oct 2014
Application12/681,814Parent of this continuation
US 10,736,848 B2Related patent
US 2010/0233251 A1Published application
US 9,539,210 B2This patent

From the US filing history. Foreign family members aren’t listed.